ResMed Shares Are Trading Lower After Rival Eli Lilly Received Approval for Zepbound as an Obstructive Sleep Apnea Treatment for Obese Adults.
ResMed Shares Are Trading Lower After Rival Eli Lilly Received Approval for Zepbound as an Obstructive Sleep Apnea Treatment for Obese Adults.
瑞思邁的股票因競爭對手禮來獲得批准將Zepbound作爲肥胖成年人阻塞性睡眠呼吸暫停治療而下跌。
ResMed Shares Are Trading Lower After Rival Eli Lilly Received Approval for Zepbound as an Obstructive Sleep Apnea Treatment for Obese Adults.
瑞思邁的股票因競爭對手禮來獲得批准將Zepbound作爲肥胖成年人阻塞性睡眠呼吸暫停治療而下跌。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。